Summary:
The purpose of this study is to evaluate the efficacy of solabegron immediate release 125mg or 175mg tablets administered twice daily to adult femaile subjects with overactive bladder.
Evaluate safety and tolerability of solabegron immediate release 125mg or 175 mg tablets administered twice daily to adult female subjects with overactive bladder for 12 weeks of dosing compared with placebo.
Qualified Participants Must:
• Be between 18-80 years of age
•
Have established OAB symptoms for 3 months prior to screening
•
Body weight over 110 lbs
•
Controlled blood pressure and blood sugar
Qualified Participants May Receive:
- Compensation for time and travel expenses
- Study related laboratory testing such as blood work and EKG
- Physicals performed by a board certified physician
- Study related medication